Tirzepatide Improves Eating Behaviors in Type 2 Diabetes Regardless of Previous GLP-1 Drug Use
In 33 Japanese T2DM patients treated with tirzepatide for 6 months, HbA1c dropped from 7.3% to 5.8%, body weight fell from 87.7 to 79.6 kg, and eating behavior scores improved — with different improvement patterns depending on prior GLP-1 RA exposure.
Quick Facts
What This Study Found
Over 6 months: HbA1c 7.3%→6.0%→5.8%. Body weight 87.7→82.0→79.6 kg. Eating behavior score 57.0→50.7→45.9. GLP-1RA-naïve (n=20): eating behavior changes mainly in first 3 months. GLP-1RA non-naïve (n=13): eating behavior changes continued through 6 months. No correlation between eating behavior changes and weight/glucose changes.
Key Numbers
33 patients, mean age 51.8 years. Tirzepatide started at 2.5 mg/week for 4 weeks, then 5.0 mg/week, for 6 months total.
How They Did This
Prospective cohort of 33 Japanese T2DM patients (mean age 51.8 years). Tirzepatide 2.5 mg/week for 4 weeks, then 5.0 mg/week. Validated eating behavior questionnaire at baseline, 3 months, and 6 months. Subgroup analysis by prior GLP-1 RA exposure.
Why This Research Matters
Weight loss drugs are often criticized as purely metabolic interventions that don't address the behavioral and psychological aspects of overeating. This study suggests tirzepatide may actually change how people relate to food — an effect that appears independent of its metabolic benefits and could contribute to more sustainable weight management.
The Bigger Picture
Tirzepatide's dual GIP/GLP-1 action may produce distinct brain effects compared to GLP-1-only drugs. The finding that eating behavior improvements don't correlate with weight loss suggests a direct central nervous system effect on food reward and eating patterns — a mechanism that could be key to long-term weight maintenance.
What This Study Doesn't Tell Us
Small sample (33 patients). No control group. Japanese population with lower BMI and tirzepatide doses than Western studies. Validated questionnaire is subjective. 6 months may not capture long-term behavioral sustainability. Eating behavior assessment doesn't distinguish between hunger reduction and true behavioral change.
Questions This Raises
- ?Do eating behavior improvements persist after tirzepatide discontinuation?
- ?Does the additional GIP agonism of tirzepatide contribute to eating behavior changes beyond what GLP-1 alone provides?
- ?Would higher tirzepatide doses (10-15 mg) produce greater eating behavior changes?
Trust & Context
- Key Stat:
- Eating score: 57.0→45.9 Tirzepatide improved validated eating behavior scores by 19% over 6 months — an effect that did not correlate with weight or glucose changes, suggesting an independent behavioral mechanism
- Evidence Grade:
- Rated preliminary: small uncontrolled cohort (33 patients). Interesting signal but needs confirmation in larger controlled studies with objective behavioral measures.
- Study Age:
- Published in 2024. Addresses the emerging question of GLP-1/GIP drug effects on eating behavior beyond appetite suppression.
- Original Title:
- Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.
- Published In:
- Journal of diabetes and its complications, 38(7), 108779 (2024)
- Authors:
- Suzuki, Toru, Sato, Tatsuya, Tanaka, Marenao, Endo, Keisuke, Nakata, Kei, Ogawa, Toshifumi, Hosaka, Itaru, Akiyama, Yukinori, Umetsu, Araya, Furuhashi, Masato
- Database ID:
- RPEP-09352
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide change how people eat, not just how much they weigh?
This study suggests yes. Patients' eating behavior scores improved significantly over 6 months, and these improvements didn't correlate with weight loss or blood sugar changes. This means tirzepatide may be changing the psychological aspects of eating — how people think about and relate to food — not just suppressing appetite.
Does it matter if you've taken a GLP-1 drug before starting tirzepatide?
Interestingly, yes — but not in the way you'd expect. Both groups (GLP-1-naïve and GLP-1-experienced) improved their eating behaviors, but on different timelines. New users saw changes mostly in the first 3 months, while those switching from GLP-1 drugs continued improving through 6 months. Both groups ultimately benefited.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09352APA
Suzuki, Toru; Sato, Tatsuya; Tanaka, Marenao; Endo, Keisuke; Nakata, Kei; Ogawa, Toshifumi; Hosaka, Itaru; Akiyama, Yukinori; Umetsu, Araya; Furuhashi, Masato. (2024). Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.. Journal of diabetes and its complications, 38(7), 108779. https://doi.org/10.1016/j.jdiacomp.2024.108779
MLA
Suzuki, Toru, et al. "Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus.." Journal of diabetes and its complications, 2024. https://doi.org/10.1016/j.jdiacomp.2024.108779
RethinkPeptides
RethinkPeptides Research Database. "Tirzepatide ameliorates eating behaviors regardless of prior..." RPEP-09352. Retrieved from https://rethinkpeptides.com/research/suzuki-2024-tirzepatide-ameliorates-eating-behaviors
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.